Biochimica et Biophysica Acta-Reviews on Cancer

Article	Citations
Modeling bladder cancer in the laboratory: Insights from patient-derived organoids	380
Role of N7-methylguanosine in gastrointestinal tumors: Molecular mechanisms and therapeutic targets	239
Targeting ferroptosis with flavonoids for cancer therapy: Mechanisms and opportunities	155
Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles	145
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective	141
Targeted drug delivery systems in Lymphoma treatment: Advances and clinical perspectives	95
The bridging role of neutrophils in the progression of inflammation-induced colorectal cancer	90
VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis	84
Unlocking the power of innate lymphoid cell plasticity in the tumor microenvironment: A revolutionary pathway for cancer immunotherapy	83
The role of protein glycosylation in colorectal cancer: From molecular pathways to clinical applications	81
Uveal melanoma modeling in mice and zebrafish	79
Spatiotemporal dynamics of the pre-metastatic niche: remodeling of lung microenvironment before breast cancer metastasis and targeted intervention strategies	78
Advances in epigenetic modifications and cervical cancer research	74
Nutrition and dietary restrictions in cancer prevention	72
ESR1 activating mutations: From structure to clinical application	70
Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer	68
Fascin-1 in primary liver cancers, perspectives for targeted therapy	68
Yin yang 1: a potential regulator of immune related diseases and cancer immunity	68
In what area of biology has a “new” type of cell death been discovered?	65
Decoding the role of FOXP3 in esophageal cancer: Underlying mechanisms and therapeutic implications	63
Detection methods for mitochondrial DNA heteroplasmy and their potential single-cell applications in cancer	62
S100A8 and S100A9 in Cancer	61
Biomarkers in high grade serous ovarian cancer	59
CCL20-CCR6 signaling in tumor microenvironment: Functional roles, mechanisms, and immunotherapy targeting	56
Extracellular vesicles in cancer therapy: Roles, potential application, and challenges	56

Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistance	53
Advances and prospects of mRNA vaccines in cancer immunotherapy	53
Long non-coding RNAs: Fundamental regulators and emerging targets of cancer stem cells	53
Insights into the role of connexins and specialized intercellular communication pathways in breast cancer: Mechanisms and applications	52
Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope	51
Unveiling anaphylatoxins: Pioneering cancer therapies through complement system insights	51
Dual perspective on autophagy in glioma: Detangling the dichotomous mechanisms of signaling pathways for therapeutic insights	49
Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans	49
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature	49
Targeting lipid metabolism in cancer metastasis	48
Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer	48
The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance	47
Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy	46
Mitochondrial metabolism in laryngeal cancer: therapeutic mechanisms and prospects	46
Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance mechanisms in prostate cancer	44
Targeting Cdc20 for cancer therapy	40
Multiple impacts of Naa10p on cancer progression: Molecular functions and clinical prospects	40
Emerging perspectives on metabolic reprogramming in the microenvironment of ovarian cancer metastasis	40
Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions	39
Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors	39
Recent insights into RNA m5C methylation modification in hepatocellular carcinoma	39
Organic nanoplatforms for metallodrugs delivery: Current advances in colorectal cancer	39
The interplay of obesity, microbiome dynamics, and innovative anti-obesity strategies in the context of endometrial cancer progression and therapeutic approaches	38
Mitochondrial dynamics and metabolic attributes regulate function of natural killer cell and infiltration in tumor microenvironment modulating disease progression	38
Organoids as a new approach in advancing cancer therapies for hematologic malignancies	38
Multifaceted roles of neutrophils in tumor microenvironment	38
The mechanics of anoikis resistance in cancer	37
STIM1-mediated calcium signalling in cancer: Its relation to tumour aggressiveness and therapeutic horizons	37
Furin-like enzyme dependency in KRAS-mutant colorectal cancer as a target for personalized treatment strategies	37
Small non-coding RNAs and pancreatic ductal adenocarcinoma: Linking diagnosis, pathogenesis, drug resistance, and therapeutic potential	37
The NLRP3 inflammasome and its role in acute myeloid leukemia onset and development	36
Nondiploid cancer cells: Stress, tolerance and therapeutic inspirations	36
Olfactomedin 4 in cancer development and progression	36
Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy	36
Targetable axes of tumor-associated macrophages: An MSF framework for precision immunotherapy	36
Vagus innervation in the gastrointestinal tumor: Current understanding and challenges	36
Targeting the triad: phenotypic plasticity, tumor microenvironment and bone microenvironment in prostate cancer bone-metastatic events	36
Current advances in comprehensive omics data mining for oncology and cancer research	36
Epithelial-Mesenchymal Transition in Cancer: A Focus on Itraconazole, a Hedgehog Inhibitor	35
Editorial Board	35
Antibody-drug conjugates in HER-2 negative breast cancers with poor prognosis	34
Combination therapy in cancer: The potential of tetrandrine as a polytherapy for acute myeloid leukemia	34
Predictive and prognostic value of PIK3CA mutations in HER2-positive breast cancer treated with tyrosine kinase inhibitors: A systematic review and meta-analysis	33
YY1: Master regulator of metabolic reprogramming in cancer	33
Cancer-associated fibroblasts-derived exosomes in colorectal cancer progression: Mechanism and therapeutic opportunities	33
Antibody-drug conjugates in breast cancer: Marching from HER2-overexpression into HER2-low	33
ASPORIN: A root of the matter in tumors and their host environment	32
Unveiling the potential of gene editing techniques in revolutionizing Cancer treatment: A comprehensive overview	32
Abnormal metabolism in hepatic stellate cells: Pandora's box of MAFLD related hepatocellular carcinoma	32
The signal hijacker: How tumors co-opt chemical, electrical, and mechanical cues to thrive	32

Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression	31
CD8+ T-cell exhaustion: Impediment to triple-negative breast cancer (TNBC) immunotherapy	31
Focus on mast cells in the tumor microenvironment: Current knowledge and future directions	31
Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies	31
Analysis of bladder cancer therapeutic drug clinical trials in mainland China and globally	31
Matrisomics: Beyond the extracellular matrix for unveiling tumor microenvironment	31
In vitro anticancer properties of anthocyanins: A systematic review	30
An overview of BAP1 biological functions and current therapeutics	30
Cellular functions, molecular signalings and therapeutic applications: Translational potential of deubiquitylating enzyme USP9X as a drug target in cancer treatment	30
Interactions between cancer cells and tumor-associated macrophages in tumor microenvironment	30
A role for RIO kinases in the crosshair of cancer research and therapy	30
The Pleiotropic role, functions and targeted therapies of LIF/LIFR axis in cancer: Old spectacles with new insights	29
Exploring the gut microbiome: A potential biomarker for cancer diagnosis, prognosis, and therapy	29
Unveiling the TGF-β/Smad signaling in renal carcinoma progression: Prognostic and therapeutic insights	29
HOXA1, a breast cancer oncogene	29
Immune archetypes TIME classification system for nasopharyngeal carcinoma: A new direction for precision immunotherapy	29
Refinement of safety and efficacy of anti-cancer chemotherapeutics by tailoring their site-specific intracellular bioavailability through transporter modulation	29
Strategies for studying immune and non-immune human and canine mammary gland cancer tumour infiltrate	29
Colorectal cancer: Metabolic interactions reshape the tumor microenvironment	28
The microbiota-m6A-metabolism axis: Implications for therapeutic strategies in gastrointestinal cancers	28
Overview of splicing variation in ovarian cancer	28
Emerging strategies to overcome PARP inhibitors' resistance in ovarian cancer	28
Schwann cells and enteric glial cells: Emerging stars in colorectal cancer	27
Carbonic anhydrase IX: An atypical target for innovative therapies in cancer	27
Taurine and cancer: Biological properties and multifaceted roles in cancer progression	27
USP7 - a crucial regulator of cancer hallmarks	27
New target DDR1: A “double-edged sword” in solid tumors	27
Research progress on the regulatory role of lactate and lactylation in tumor microenvironment	27
Dual role of Snail1 as transcriptional repressor and activator	27
M6A methylation in tumor immune microenvironment: Multidimensional mechanism and targeted therapy strategies	27
Targeting the tumor immune microenvironment in chordoma: From mechanistic insights to therapeutic breakthroughs	26
Unraveling molecular aberrations and pioneering therapeutic strategies in osteosarcoma	26
Dietary sugar intervention: A promising approach for cancer therapy	26
Exosomal non-coding RNAs (ncRNAs) as potential biomarkers in tumor early diagnosis	26
A novel approach to reducing disparities in health outcomes by enhancing interpretation of cancer clinical trials for underrepresented patient groups	26
Key methylation modifications in glioma stem cells	25
New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas	25
Potentially diagnostic and prognostic roles of piRNAs/PIWIs in pancreatic cancer: A review	24
MXene-based functional nanodrugs towards anticancer strategy and augmented sonodynamic therapy	24
Harnessing microRNAs in lung cancer: The future of diagnosis and precision therapy	24
To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3	24
Stress granules dynamics and promising functions in pancreatic cancer	24
Epigenetic regulation of cancer-associated fibroblast heterogeneity	23
From resistance to resilience: Uncovering chemotherapeutic resistance mechanisms; insights from established models	23
Metabolic insights into TAMs and the tumor immune microenvironment: Regulatory mechanisms and therapeutic interventions	23
Role of F-box proteins in human upper gastrointestinal tumors	23
Proteomics of post-translational modifications in colorectal cancer: Discovery of new biomarkers	23
Scientific and clinical relevance of non-cellular tumor microenvironment components in ovarian cancer chemotherapy resistance	23
SNARE proteins: Core engines of membrane fusion in cancer	23
Augmentation of the EPR effect by mild hyperthermia to improve nanoparticle delivery to the tumor	22
Sequencing of antibody drug conjugates in breast cancer: Evidence gap and future directions	22
Artificial intelligence and allied subsets in early detection and preclusion of gynecological cancers	22
Perspectives and mechanisms for targeting mitotic catastrophe in cancer treatment	22
Role of macrophage PKM2 in inflammation and tumor progression and its targeted therapy	22
Expression and function of NF-Y subunits in cancer	21
Radiotherapy modulates autophagy to reshape the tumor immune microenvironment to enhance anti-tumor immunity in esophageal cancer	21
Spatiotemporal heterogeneity and clinical challenge of pancreatic neuroendocrine tumors	21
Advances in the combination of immunoadjuvants and tumor ablation: Mediating immune effects to enhance anti-tumor efficacy	21
A special subtype: Revealing the potential intervention and great value of KRAS wildtype pancreatic cancer	21
Understanding the role of DNA methylation in colorectal cancer: Mechanisms, detection, and clinical significance	21
Role of Yin Yang 1 (YY1) on microenvironment, signaling pathways, and epigenetics in lung cancer	21
Corrigendum to “Snail1 as a key prognostic biomarker of cancer-associated fibroblasts in breast tumors” [Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, volume 1880 (2025) / 189316]	21
The neoantigens derived from transposable elements – A hidden treasure for cancer immunotherapy	21
SF3B1 mutations in spliceosome-driven tumorigenesis: From splicing dysregulation to signaling network rewiring and therapeutic targeting	21
Gut-liver axis drives the triple mechanism of liver inflammation-carcinogenesis: Microbial-immune-metabolic network	21
Research progress of mitochondria and cytoskeleton crosstalk in tumour development	20
Emerging roles of PIWI-interacting RNAs (piRNAs) and PIWI proteins in head and neck cancer and their potential clinical implications	20
Novel insights in the diagnosis and treatment of non-small cell lung cancer: Post-translational modification of proteins	20
Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review	20
The correlation between gut and intra-tumor microbiota and PDAC: Etiology, diagnostics and therapeutics	20
Histone deacetylase complexes: Structure, regulation and function	19
Tumoral heterogeneity in neuroblastoma	19
Tumor microenvironment diversity and plasticity in cancer multidrug resistance	19
B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer	19
Dual roles of human endogenous retroviruses in cancer progression and antitumor immune response	19
Editorial Board	19
Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives	19
Unraveling metastatic timing: insights and challenges from genomic evolution	19
Reflecting on the cardiac toxicity in non-small cell lung cancer in the era of immune checkpoint inhibitors therapy combined with thoracic radiotherapy	19
Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53	19

Finding the junction between claudins and endometrial carcinoma	19
Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors	18
The interplay between microbiome and host factors in pathogenesis and therapy of head and neck cancer	18
Dietary and serum advanced glycation end-products and clinical outcomes in breast cancer	18
The comparison of pathogenic role and mechanism of Kallistatin and PEDF in tumors	18
The role of TRIM25 in the occurrence and development of cancers and inflammatory diseases	18
Cancer stem cells in focus: Deciphering the dynamic functional landscape of stemness in cancer	18
Anoikis and NETosis in colorectal cancer liver metastasis: the relationship and perspectives	18
Nanoparticulate delivery and targeting of RNA to the brain	18
A review exploring the fusion of oncolytic viruses and cancer immunotherapy: An innovative strategy in the realm of cancer treatment	18
The role of exosomes in the tumour microenvironment on macrophage polarisation	18
CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways	18
Role of the intratumoral microbiome in tumor progression and therapeutics implications	18
Editorial Board	18
Comprehensive insights of etiological drivers of hepatocellular carcinoma: Fostering targeted nano delivery to anti-cancer regimes	18
Thymic epithelial tumor medical treatment: A narrative review	18
Clinical and Molecular Attributes and Evaluation of Pancreatic Cystic Neoplasm	17
Cancer-associated fungi: An emerging powerful player in cancer immunotherapy	17
Advances in glioma models using in vivo electroporation to highjack neurodevelopmental processes	17
Unveiling Cuproptosis: Mechanistic insights, roles, and leading advances in oncology	17
Protein induced by vitamin K absence or antagonist II: Experience to date and future directions	17
Epigenetic mechanisms of cancer progression and therapy resistance in estrogen-receptor (ER+) breast cancer	17
The potential of TRP channels as new prognostic and therapeutic targets against prostate cancer progression	17
TERT promoter mutations in gliomas: Molecular roles in tumorigenesis, metastasis, diagnosis, prognosis, therapeutic targeting, and drug resistance	17
Metabolic reprogramming in breast cancer: Pathways driving progression, drug resistance, and emerging therapeutics	17
Biological function, regulatory mechanism, and clinical application of mannose in cancer	17
Interstitial fluid pressure as an emerging biomarker in solid tumors	17
Snake venom-derived peptides as anticancer candidates: Pioneering next-generation therapies	17
Molecular and immune pathobiology of human angiosarcoma	17
Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy	17
Corrigendum to “Unveiling the TGF-β/Smad signaling in renal carcinoma progression: Prognostic and therapeutic insights” [Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Volume 1880, Issue 4,	16
GSDM family and glioma	16
EV-mediated asymmetrical crosstalk between CAFs and cancer cells in the tumor microenvironment	16
Unravelling the complexity of lncRNAs in autophagy to improve potential cancer therapy	16
Bioelectronic medicines: Therapeutic potential and advancements in next-generation cancer therapy	16
Current advances and clinical perspectives of anti-angiogenic therapy combined with immune checkpoint inhibitors in digestive system malignancies	16
Improving the efficacy of anti-EGFR drugs in GBM: Where we are going?	16
Decoding the role of intratumoral microbiota in gastric cancer	16
Osteoblasts in bone metastasis: Key players in the tumor microenvironment and therapeutic targets	16
Combination therapies with Wnt signaling inhibition: A better choice for prostate cancer treatment	16
Key subunits of γ-secretase complex and breast cancer progression: biological function, regulation mode and therapeutic potential	16
Roles of K(H)SRP in modulating gene transcription throughout cancer progression: Insights from cellular studies to clinical perspectives	16
Advances in tuft cells, a chemosensory cell in sequential diseases of the pancreas	16
Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits	16
Histone acetyltransferase HBO1 in cancer biology: Essential mechanisms and implications for targeted therapeutics	16